Assessment of a New Apexification Method for Patients Presenting a Non Vital Immature Tooth
Launched by ASSISTANCE PUBLIQUE - HÔPITAUX DE PARIS · May 10, 2007
Trial Information
Current as of July 06, 2025
Completed
Keywords
ClinConnect Summary
36 patients aged 6 to 18 and presenting a non vital immature tooth will be included in the study (inclusion period: 12 months). These patients will be randomly divided into two groups: one treated with MTA®, and the other one with calcium hydroxide. For each patient, the total duration of the study will be 12 months. Recalls will be performed at 15 and 21 days and then at 3, 6 and 12 months to assess by clinical and X-ray exams the main success criterion: presence of a calcified apical barrier or not. Additional criterions such as presence of clinical symptoms or not, apical morphology and ...
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Indication of apexification treatment of an anterior immature tooth
- • Patients aged 6 to 18
- • Enlightened agreement of the patient and his/her legal representatives
- • Prerequisite medical examination
- Exclusion Criteria:
- • General disease
- • diabetes
- • immunosuppression of whatever origin (AIDS, drugs, ...)
- • severe asthma
- • chronical disease requiring treatment
- • eating disorders (anorexia, bulimia, malnutrition, ...) Oral disease
- • periodontal disease
- • Administration of corticoids in a period of 3 months preceding the inclusion
- • Patient with no social security cover
About Assistance Publique Hôpitaux De Paris
Assistance Publique - Hôpitaux de Paris (AP-HP) is a leading public hospital system in France, renowned for its commitment to healthcare excellence and innovative medical research. As a prominent clinical trial sponsor, AP-HP plays a pivotal role in advancing medical knowledge and improving patient care through rigorous scientific investigations across a wide range of therapeutic areas. With a focus on collaboration and interdisciplinary approaches, AP-HP leverages its extensive network of hospitals and expert clinicians to facilitate high-quality clinical trials that adhere to the highest ethical and regulatory standards, ultimately aiming to translate research findings into tangible health benefits for diverse patient populations.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Paris, , France
Patients applied
Trial Officials
Jean-Jacques Lasfargues, Dentist PhD
Principal Investigator
Hôpital Bretonneau - Paris
Raphaël SERREAU, MD, PhD
Study Director
URC Paris Centre
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials